Tumor immune therapy: Lessons from infection and implications for cancer - Can IL-7 help overcome immune inhibitory networks?

European Journal of Immunology

Volumn 40, Issue 7, 2010, Pages 1852-1861

  Pellegrini, Marc ^a   Mak, Tak W ^b  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Cancer; IL 7; Immunity; Infection

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; CYTOKINE; DNA METHYLTRANSFERASE INHIBITOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HISTONE DEACETYLASE INHIBITOR; IMMUNOMODULATING AGENT; INTERFERON; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 21; INTERLEUKIN 7; MONOCLONAL ANTIBODY; TUMOR ANTIGEN; TUMOR VACCINE; AUTOANTIGEN;

ADAPTIVE IMMUNITY; ADOPTIVE IMMUNOTHERAPY; ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CELL THERAPY; CLINICAL TRIAL; DRUG MECHANISM; GENE MUTATION; HOMEOSTASIS; HUMAN; INFECTION; KIDNEY CARCINOMA; MELANOMA; METASTASIS; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; T LYMPHOCYTE; TH17 CELL; TUMOR IMMUNITY; ANIMAL; IMMUNITY; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASMS; TUMOR ESCAPE;

ANIMALS; ANTIGENS, NEOPLASM; AUTOANTIGENS; HUMANS; IMMUNE TOLERANCE; IMMUNITY; IMMUNOTHERAPY; INTERLEUKIN-7; NEOPLASMS; TUMOR ESCAPE;

EID: 77954125915     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201040603     Document Type: Review

References (118)

1. Virgin, H. W., Wherry, E. J. and Ahmed, R., Redefining chronic viral infection. Cell 2009. 138: 30-50.
2. Peggs, K. S., Quezada, S. A. and Allison, J. P., Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy. Immunol. Rev. 2008. 224: 141-165.
3. Klein, G. and Klein, E., Immune surveillance against virus-induced tumors and nonrejectability of spontaneous tumors: contrasting consequences of host versus tumor evolution. Proc. Natl. Acad. Sci. USA 1977. 74: 2121-2125.
4. Karin, M. and Greten, F. R., NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat. Rev. Immunol. 2005. 5: 749-759.
5. Willimsky, G. and Blankenstein, T., The adaptive immune response to sporadic cancer. Immunol. Rev. 2007. 220: 102-112.
6. Sioud, M., Does our current understanding of immune tolerance, autoimmunity, and immunosuppressive mechanisms facilitate the design of efficient cancer vaccines? Scand. J. Immunol. 2009. 70: 516-525.
7. Drake, C. G., Jaffee, E. and Pardoll, D. M., Mechanisms of immune evasion by tumors. Adv. Immunol. 2006. 90: 51-81.
8. Takeuchi, O. and Akira, S., Pattern recognition receptors and inflammation. Cell 2010. 140: 805-820.
9. Rey, J., Veuillen, C., Vey, N., Bouabdallah, R. and Olive, D., Natural killer and gammadelta T cells in haematological malignancies: enhancing the immune effectors. Trends Mol. Med. 2009. 15: 275-284.
10. Ohashi, P. S., Negative selection and autoimmunity. Curr. Opin. Immunol. 2003. 15: 668-676.
11. Seya, T., Shime, H., Ebihara, T., Oshiumi, H. and Matsumoto, M., Pattern recognition receptors of innate immunity and their application to tumor immunotherapy. Cancer Sci. 2010. 101: 313-320.
12. Ghiringhelli, F., Apetoh, L., Tesniere, A., Aymeric, L., Ma, Y., Ortiz, C., Vermaelen, K. et al., Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat. Med. 2009. 15: 1170-1178.
13. Zitvogel, L., Apetoh, L., Ghiringhelli, F. and Kroemer, G., Immunological aspects of cancer chemotherapy. Nat. Rev. Immunol. 2008. 8: 59-73.
14. Terme, M., Ullrich, E., Delahaye, N. F., Chaput, N. and Zitvogel, L., Natural killer cell-directed therapies: moving from unexpected results to successful strategies. Nat. Immunol. 2008. 9: 486-494.
15. Parmiani, G., De Filippo, A., Novellino, L. and Castelli, C., Unique human tumor antigens: immunobiology and use in clinical trials. J. Immunol. 2007. 178: 1975-1979. (Pubitemid 46233392)
16. Teague, R. M., Sather, B. D., Sacks, J. A., Huang, M. Z., Dossett, M. L., Morimoto, J., Tan, X. et al., Interleukin-15 rescues tolerant CD8+ T cells for use in adoptive immunotherapy of established tumors. Nat. Med. 2006. 12: 335-341.
17. Bendle, G. M., Xue, S. A., Holler, A. and Stauss, H. J., A study of T cell tolerance to the tumor-associated antigen MDM2: cytokines can restore antigen responsiveness, but not high avidity T cell function. PLoS One 2007. 2: e353.
18. Pellegrini, M., Calzascia, T., Elford, A. R., Shahinian, A., Lin, A. E., Dissanayake, D., Dhanji, S. et al., Adjuvant IL-7 antagonizes multiple cellular and molecular inhibitory networks to enhance immunotherapies. Nat. Med. 2009. 15: 528-536.
19. Rosenberg, S. A., Restifo, N. P., Yang, J. C., Morgan, R. A. and Dudley, M. E., Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat. Rev. Cancer 2008. 8: 299-308.
20. Pittet, M. J., Behavior of immune players in the tumor microenvironment. Curr. Opin. Oncol. 2009. 21: 53-59.
21. Rabinovich, G. A., Gabrilovich, D. and Sotomayor, E. M., Immunosuppressive strategies that are mediated by tumor cells. Annu. Rev. Immunol. 2007. 25: 267-296.
22. Murdoch, C., Muthana, M., Coffelt, S. B. and Lewis, C. E., The role of myeloid cells in the promotion of tumour angiogenesis. Nat. Rev. Cancer 2008. 8: 618-631.
23. Allan, S. E., Broady, R., Gregori, S., Himmel, M. E., Locke, N., Roncarolo, M. G., Bacchetta, R. and Levings, M. K., CD4+ T-regulatory cells: toward therapy for human diseases. Immunol. Rev. 2008. 223: 391-421.
24. Ruprecht, C. R., Gattorno, M., Ferlito, F., Gregorio, A., Martini, A., Lanzavecchia, A. and Sallusto, F., Coexpression of CD25 and CD27 identifies FoxP3+ regulatory T cells in inflamed synovia. J. Exp. Med. 2005. 201: 1793-1803.
25. Ben Ahmed, M., Belhadj Hmida, N., Moes, N., Buyse, S., Abdeladhim, M., Louzir, H. and Cerf-Bensussan, N., IL-15 renders conventional lymphocytes resistant to suppressive functions of regulatory T cells through activation of the phosphatidylinositol 3-kinase pathway. J. Immunol. 2009. 182: 6763-6770.
26. Cui, Y., Zhang, H., Meadors, J., Poon, R., Guimond, M. and Mackall, C. L., Harnessing the physiology of lymphopenia to support adoptive immunotherapy in lymphoreplete hosts. Blood 2009. 114: 3831-3840.
27. Peggs, K. S., Quezada, S. A. and Allison, J. P., Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists. Clin. Exp. Immunol. 2009. 157: 9-19.
28. Becker, Y., Molecular immunological approaches to biotherapy of human cancers - a review, hypothesis and implications. Anticancer Res. 2006. 26: 1113-1134.
29. Katz, J. B., Muller, A. J. and Prendergast, G. C., Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape. Immunol. Rev. 2008. 222: 206-221.
30. Lob, S., Konigsrainer, A., Rammensee, H. G., Opelz, G. and Terness, P., Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees? Nat. Rev. Cancer 2009. 9: 445-452.
31. Yu, H., Pardoll, D. and Jove, R., STATs in cancer inflammation and immunity: a leading role for STAT3. Nat. Rev. Cancer 2009. 9: 798-809.
32. Melero, I., Hervas-Stubbs, S., Glennie, M., Pardoll, D. M. and Chen, L., Immunostimulatory monoclonal antibodies for cancer therapy. Nat. Rev. Cancer 2007. 7: 95-106.
33. Capitini, C. M., Fry, T. J. and Mackall, C. L., Cytokines as adjuvants for vaccine and cellular therapies for cancer. Am. J. Immunol. 2009. 5: 65-83.
34. Peggs, K. S., Quezada, S. A., Chambers, C. A., Korman, A. J. and Allison, J. P., Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J. Exp. Med. 2009. 206: 1717-1725.
35. Lin, A. E. and Mak, T.W., The role of E3 ligases in autoimmunity and the regulation of autoreactive T cells. Curr. Opin. Immunol. 2007. 19: 665-673.
36. Yoshimura, A., Naka, T. and Kubo, M., SOCS proteins, cytokine signalling and immune regulation. Nat. Rev. Immunol. 2007. 7: 454-465.
37. Huang,G. N., Huso, D. L., Bouyain, S., Tu, J., McCorkell, K. A., May, M. J., Zhu, Y. et al., NFAT binding and regulation of T cell activation by the cytoplasmic scaffolding Homer proteins. Science 2008. 319: 476-481.
38. Zha, Y., Marks, R., Ho, A. W., Peterson, A. C., Janardhan, S., Brown, I., Praveen, K. et al., T cell anergy is reversed by active Ras and is regulated by diacylglycerol kinase-alpha. Nat. Immunol. 2006. 7: 1166-1173.
39. Safford, M., Collins, S., Lutz, M. A., Allen, A., Huang, C. T., Kowalski, J., Blackford, A. et al., Egr-2 and Egr-3 are negative regulators of T cell activation. Nat. Immunol. 2005. 6: 472-480.
40. Li, W. Q., Jiang, Q., Aleem, E., Kaldis, P., Khaled, A. R. and Durum, S. K., IL-7 promotes T cell proliferation through destabilization of p27Kip1. J. Exp. Med. 2006. 203: 573-582.
41. Calzascia, T., Pellegrini, M., Lin, A., Garza, K. M., Elford, A. R., Shahinian, A., Ohashi, P. S. and Mak, T. W., CD4 T cells, lymphopenia, and IL-7 in a multistep pathway to autoimmunity. Proc. Natl. Acad. Sci. USA 2008. 105: 2999-3004.
42. Dunn, G. P., Koebel, C. M. and Schreiber, R. D., Interferons, immunity and cancer immunoediting. Nat. Rev. Immunol. 2006. 6: 836-848.
43. Melchionda, F., Fry, T. J., Milliron, M. J., McKirdy, M. A., Tagaya, Y. and Mackall, C. L., Adjuvant IL-7 or IL-15 overcomes immunodominance and improves survival of the CD81 memory cell pool. J. Clin. Invest. 2005. 115: 1177-1187.
44. Sportes, C., Hakim, F. T., Memon, S. A., Zhang, H., Chua, K. S., Brown, M. R., Fleisher, T. A. et al., Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets. J. Exp. Med. 2008. 205: 1701-1714.
45. Chan, C. J., Andrews, D. M. and Smyth, M. J., Can NK cells be a therapeutic target in human cancer? Eur. J. Immunol. 2008. 38: 2964-2968.
46. Karpf, A. R., A potential role for epigenetic modulatory drugs in the enhancement of cancer/germ-line antigen vaccine efficacy. Epigenetics 2006. 1: 116-120.
47. Reits, E. A., Hodge, J. W., Herberts, C. A., Groothuis, T. A., Chakraborty, M., Wansley, E. K. et al., Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J. Exp. Med. 2006. 203: 1259-1271.
48. Weiner, L. M., Surana, R. and Wang, S., Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat. Rev. Immunol. 2010. 10: 317-327.
49. Bhave, N. S. and Carson, W. E., 3rd., Immune modulation with interleukin-21. Ann. NY Acad. Sci. 2009. 1182: 39-46.
50. Overwijk, W. W. and Schluns, K. S., Functions of gammaC cytokines in immune homeostasis: current and potential clinical applications. Clin. Immunol. 2009. 132: 153-165.
51. Rochman, Y., Spolski, R. and Leonard, W. J., New insights into the regulation of T cells by gamma(c) family cytokines. Nat. Rev. Immunol. 2009. 9: 480-490.
52. Eklund, J. W. and Kuzel, T. M., A review of recent findings involving interleukin-2-based cancer therapy. Curr. Opin. Oncol. 2004. 16: 542-546.
53. Williams, M. A., Tyznik, A. J. and Bevan, M. J., Interleukin-2 signals during priming are required for secondary expansion of CD8+ memory T cells. Nature 2006. 441: 890-893.
54. Malek, T. R. and Bayer, A. L., Tolerance, not immunity, crucially depends on IL-2. Nat. Rev. Immunol. 2004. 4: 665-674.
55. Zhang, H., Chua, K. S., Guimond, M., Kapoor, V., Brown, M. V., Fleisher, T. A. and Long, L. M. Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+CD25+ regulatory T cells. Nat. Med. 2005. 11: 1238-1243.
56. Liu, R., Zhou, Q., La Cava, A., Campagnolo, D. I., Van Kaer, L. and Shi, F. D., Expansion of regulatory T cells via IL-2/anti-IL-2 mAb complexes suppresses experimental myasthenia. Eur. J. Immunol. 2010. 40: 1577-1589.
57. Boyman, O., Kovar, M., Rubinstein, M. P., Surh, C. D. and Sprent, J., Selective stimulation of T cell subsets with antibody-cytokine immune complexes. Science 2006. 311: 1924-1927.
58. Waldmann, T. A., The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat. Rev. Immunol. 2006. 6: 595-601.
59. Dubois, S., Mariner, J., Waldmann, T. A. and Tagaya, Y., IL-15Ralpha recycles and presents IL-15 In trans to neighboring cells. Immunity 2002. 17: 537-547. (Pubitemid 35351500)
60. Kennedy, M. K., Glaccum, M., Brown, S. N., Butz, E. A., Viney, J. L., Embers, M., Matsuki, N. et al., Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J. Exp. Med. 2000. 191: 771-780.
61. Lodolce, J. P., Boone, D. L., Chai, S., Swain, R. E., Dassopoulos, T., Trettin, S. and Ma, A., IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation. Immunity 1998. 9: 669-676.
62. Zhao, H., Nguyen, H. and Kang, J., Interleukin 15 controls the generation of the restricted T cell receptor repertoire of gamma delta intestinal intraepithelial lymphocytes. Nat. Immunol. 2005. 6: 1263-1271.
63. Ullrich, E., Bonmort, M., Mignot, G., Jacobs, B., Bosisio, D., Sozzani, S., Jalil, A. et al., Trans-presentation of IL-15 dictates IFN-producing killer dendritic cells effector functions. J. Immunol. 2008. 180: 7887-7897.
64. Klebanoff, C. A., Finkelstein, S. E., Surman, D. R., Lichtman, M. K., Gattinoni, L., Theoret, M. R., Grewal, N. et al., IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. Proc. Natl. Acad. Sci. USA 2004. 101: 1969-1974.
65. Epardaud, M., Elpek, K. G., Rubinstein, M. P., Yonekura, A. R., Bellemare-Pelletier, A., Bronson, R., Hamerman, J. A. et al., Interleukin-15/interleukin-15R alpha complexes promote destruction of established tumors by reviving tumor-resident CD8+ T cells. Cancer Res. 2008. 68: 2972-2983.
66. Roychowdhury, S., May, K. F., Jr., Tzou, K. S., Lin, T., Bhatt, D., Freud, A. G., Guimond, M. et al., Failed adoptive immunotherapy with tumor-specific T cells: reversal with low-dose interleukin 15 but not low-dose interleukin 2. Cancer Res. 2004. 64: 8062-8067.
67. Stoklasek, T. A., Schluns, K. S. and Lefrancois, L., Combined IL-15/IL-15Ralpha immunotherapy maximizes IL-15 activity in vivo. J. Immunol. 2006. 177: 6072-6080. (Pubitemid 44628822)
68. Ozaki, K., Spolski, R., Feng, C. G., Qi, C. F., Cheng, J., Sher, A., Morse, H. C., 3rd. et al., A critical role for IL-21 in regulating immunoglobulin production. Science 2002. 298: 1630-1634.
69. Skak, K., Frederiksen, K. S. and Lundsgaard, D., Interleukin-21 activates human natural killer cells and modulates their surface receptor expression. Immunology 2008. 123: 575-583.
70. Kasaian, M. T., Whitters, M. J., Carter, L. L., Lowe, L. D., Jussif, J. M., Deng, B., Johnson, K. A. et al., IL-21 limits NK cell responses and promotes antigen-specific T cell activation: a mediator of the transition from innate to adaptive immunity. Immunity 2002. 16: 559-569.
71. Parrish-Novak, J., Dillon, S. R., Nelson, A., Hammond, A., Sprecher, C., Gross, J. A., Johnston, J. et al., Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature 2000. 408: 57-63.
72. Zeng, R., Spolski, R., Finkelstein, S. E., Oh, S., Kovanen, P. E., Hinrichs, C. S., Pise-Masison, C. A. et al., Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function. J. Exp. Med. 2005. 201: 139-148.
73. Liu, S., Lizee, G., Lou, Y., Liu, C., Overwijk,W.W.,Wang, G. and Hwu, P., IL-21 synergizes with IL-7 to augment expansion and anti-tumor function of cytotoxic T cells. Int. Immunol. 2007. 19: 1213-1221.
74. Frederiksen, K. S., Lundsgaard, D., Freeman, J. A., Hughes, S. D., Holm, T. L., Skrumsager, B. K., Petri, A. et al., IL-21 induces in vivo immune activation of NK cells and CD8(+) T cells in patients with metastatic melanoma and renal cell carcinoma. Cancer Immunol. Immunother. 2008. 57: 1439-1449.
75. Yi, J. S., Du, M. and Zajac, A. J., A vital role for interleukin-21 in the control of a chronic viral infection. Science 2009. 324: 1572-1576.
76. Frohlich, A., Kisielow, J., Schmitz, I., Freigang, S., Shamshiev, A. T., Weber, J., Marsland, B. J. et al., IL-21R on T cells is critical for sustained functionality and control of chronic viral infection. Science 2009. 324: 1576-1580.
77. Elsaesser, H., Sauer, K. and Brooks, D. G., IL-21 is required to control chronic viral infection. Science 2009. 324: 1569-1572.
78. Moroz, A., Eppolito, C., Li, Q., Tao, J., Clegg, C. H. and Shrikant, P. A., IL-21 enhances and sustains CD8+ T cell responses to achieve durable tumor immunity: comparative evaluation of IL-2, IL-15, and IL-21. J. Immunol. 2004. 173: 900-909.
79. Ma, H. L., Whitters, M. J., Konz, R. F., Senices, M., Young, D. A., Grusby, M. J., Collins, M. and Dunussi-Joannopoulos, K., IL-21 activates both innate and adaptive immunity to generate potent antitumor responses that require perforin but are independent of IFN-gamma. J. Immunol. 2003. 171: 608-615. (Pubitemid 36871368)
80. Wang, G., Tschoi, M., Spolski, R., Lou, Y., Ozaki, K., Feng, C., Kim, G. et al., In vivo antitumor activity of interleukin 21 mediated by natural killer cells. Cancer Res. 2003. 63: 9016-9022.
81. Korn, T., Bettelli, E., Gao, W., Awasthi, A., Jager, A., Strom, T. B., Oukka, M. and Kuchroo, V. K., IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature 2007. 448: 484-487.
82. Nurieva, R., Yang, X. O., Martinez, G., Zhang, Y., Panopoulos, A. D., Ma, L., Schluns, K. et al., Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature 2007. 448: 480-483.
83. Martin-Orozco, N., Muranski, P., Chung, Y., Yang, X. O., Yamazaki, T., Lu, S., Hwu, P. et al., T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity 2009. 31: 787-798.
84. Muranski, P., Boni, A., Antony, P. A., Cassard, L., Irvine, K. R., Kaiser, A., Paulos, C. M. et al., Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood 2008. 112: 362-373.
85. Thompson, J. A., Curti, B. D., Redman, B. G., Bhatia, S., Weber, J. S., Agarwala, S. S., Sievers, E. L. et al., Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma. J. Clin. Oncol. 2008. 26: 2034-2039.
86. Davis, I. D., Brady, B., Kefford, R. F., Millward, M., Cebon, J., Skrumsager, B. K., Mouritzen, U. et al., Clinical and biological efficacy of recombinant human interleukin-21 in patients with stage IV malignant melanoma without prior treatment: a phase IIa trial. Clin. Cancer Res. 2009. 15: 2123-2129.
87. Davis, I. D., Skrumsager, B. K., Cebon, J., Nicholaou, T., Barlow, J. W., Moller, N. P., Skak, K. et al., An open-label, two-arm, phase I trial of recombinant human interleukin-21 in patients with metastatic melanoma. Clin. Cancer Res. 2007. 13: 3630-3636.
88. Disis, M. L., Bernhard, H. and Jaffee, E. M., Use of tumour-responsive T cells as cancer treatment. Lancet 2009. 373: 673-683.
89. Melief, C. J., Cancer immunotherapy by dendritic cells. Immunity 2008. 29: 372-383.
90. Yamanaka, R., Dendritic-cell- and peptide-based vaccination strategies for glioma. Neurosurg. Rev. 2009. 32: 265-273; discussion 273.
91. Dranoff, G., Targets of protective tumor immunity. Ann. NY Acad. Sci. 2009. 1174: 74-80.
92. Harzstark, A. L. and Small, E. J., Sipuleucel-T for the treatment of prostate cancer. Drugs Today (Barc) 2008. 44: 271-278.
93. Hunder, N. N., Wallen, H., Cao, J., Hendricks, D. W., Reilly, J. Z., Rodmyre, R., Jungbluth, A. et al., Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N. Engl. J. Med .2008. 358: 2698-2703.
94. Morgan, R. A., Dudley, M. E.,Wunderlich, J. R., Hughes, M. S., Yang, J. C., Sherry, R. M., Royal, R. E. et al., Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006. 314: 126-129.
95. Ringden, O., Karlsson, H., Olsson, R., Omazic, B. and Uhlin, M., The allogeneic graft-versus-cancer effect. Br. J. Haematol. 2009. 147: 614-633.
96. Ruggeri, L., Capanni, M., Urbani, E., Perruccio, K., Shlomchik, W. D., Tosti, A., Posati, S. et al., Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002. 295: 2097-2100.
97. Miller, J. S., Soignier, Y., Panoskaltsis-Mortari, A., McNearney, S. A., Yun, G. H., Fautsch, S. K., McKenna, D. et al., Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005. 105: 3051-3057.
98. Passweg, J. R., Stern, M., Koehl, U., Uharek, L. and Tichelli, A., Use of natural killer cells in hematopoetic stem cell transplantation. Bone Marrow Transplant. 2005. 35: 637-643. (Pubitemid 40520947)
99. Capitini, C. M., Chisti, A. A. and Mackall, C. L., Modulating T-cell homeostasis with IL-7: preclinical and clinical studies. J. Intern. Med. 2009. 266: 141-153.
100. Vosshenrich,C. A., Garcia-Ojeda, M. E., Samson-Villeger, S. I., Pasqualetto, V., Enault, L., Richard-Le Goff, O., Corcuff, E. et al., A thymic pathway of mouse natural killer cell development characterized by expression of GATA-3 and CD127. Nat. Immunol. 2006. 7: 1217-1224.
101. Satoh-Takayama, N., Lesjean-Pottier, S., Vieira, P., Sawa, S., Eberl, G., Vosshenrich, C. A. and Di Santo, J. P., IL-7 and IL-15 independently program the differentiation of intestinal CD3-NKp46+ cell subsets from Id2-dependent precursors. J. Exp. Med. 2010. 207: 273-280.
102. Schmutz, S., Bosco, N., Chappaz, S., Boyman, O., Acha-Orbea, H., Ceredig, R., Rolink, A. G. and Finke, D., Cutting edge: IL-7 regulates the peripheral pool of adult ROR gamma+ lymphoid tissue inducer cells. J. Immunol. 2009. 183: 2217-2221.
103. Meier, D., Bornmann, C., Chappaz, S., Schmutz, S., Otten, L. A., Ceredig, R., Acha-Orbea, H. and Finke, D., Ectopic lymphoid-organ development occurs through interleukin 7-mediated enhanced survival of lymphoid-tissue-inducer cells. Immunity 2007. 26: 643-654.
104. Vogt, T. K., Link, A., Perrin, J., Finke, D. and Luther, S. A., Novel function for interleukin-7 in dendritic cell development. Blood 2009. 113: 3961-3968.
105. Barata, J. T., Cardoso, A. A., Nadler, L. M. and Boussiotis, V. A., Interleukin-7 promotes survival and cell cycle progression of T-cell acute lymphoblastic leukemia cells by down-regulating the cyclin-dependent kinase inhibitor p27kip1. Blood 2001. 98: 1524-1531.
106. Boussiotis, V. A., Barber, D. L., Nakarai, T., Freeman, G. J., Gribben, J. G., Bernstein, G. M., D'Andrea, A. D. et al., Prevention of T cell anergy by signaling through the gamma c chain of the IL-2 receptor. Science 1994. 266: 1039-1042.
107. Boussiotis, V. A., Freeman, G. J., Taylor, P. A., Berezovskaya, A., Grass, I., Blazar, B. R. and Nadler, L. M., p27kip1 functions as an anergy factor inhibiting interleukin 2 transcription and clonal expansion of alloreactive human and mouse helper T lymphocytes. Nat. Med. 2000. 6: 290-297.
108. Tamang, D. L., Redelman, D., Alves, B. N., Vollger, L., Bethley, C. and Hudig, D., Induction of granzyme B and T cell cytotoxic capacity by IL-2 or IL-15 without antigens: multiclonal responses that are extremely lytic if triggered and short-lived after cytokine withdrawal. Cytokine 2006. 36: 148-159.
109. Kanai, T., Nemoto, Y., Kamada, N., Totsuka, T., Hisamatsu, T., Watanabe, M. and Hibi, T., Homeostatic (IL-7) and effector (IL-17) cytokines as distinct but complementary target for an optimal therapeutic strategy in inflammatory bowel disease. Curr. Opin. Gastroenterol. 2009. 25: 306-313.
110. Verhoeven, D. H., de Hooge, A. S., Mooiman, E. C., Santos, S. J., ten Dam, M. M., Gelderblom, H., Melief, C. J. et al., NK cells recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1 receptor dependent pathways. Mol. Immunol. 2008. 45: 3917-3925.
111. Castriconi, R., Daga, A., Dondero, A., Zona, G., Poliani, P. L., Melotti, A., Griffero, F. et al., NK cells recognize and kill human glioblastoma cells with stem cell-like properties. J. Immunol. 2009. 182: 3530-3539.
112. Brilot, F., Strowig, T., Roberts, S. M., Arrey, F. and Munz, C., NK cell survival mediated through the regulatory synapse with human DCs requires IL-15Ralpha. J. Clin. Invest. 2007. 117: 3316-3329.
113. Lucas, M., Schachterle, W., Oberle, K., Aichele, P. and Diefenbach, A., Dendritic cells prime natural killer cells by trans-presenting interleukin 15. Immunity 2007. 26: 503-517.
114. Rosenberg, S. A., Sportes, C., Ahmadzadeh, M., Fry, T. J., Ngo, L. T., Schwarz, S. L., Stetler-Stevenson, M. et al., IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells. J. Immunother. 2006. 29: 313-319.
115. Moller, P., Sun, Y., Dorbic, T., Alijagic, S., Makki, A., Jurgovsky, K., Schroff, M. et al., Vaccination with IL-7 gene-modified autologous melanoma cells can enhance the anti-melanoma lytic activity in peripheral blood of patients with a good clinical performance status: a clinical phase I study. Br. J. Cancer 1998. 77: 1907-1916.
116. Hafler, D. A., Compston, A., Sawcer, S., Lander, E. S., Daly, M. J., De Jager, P. L., de Bakker, P. I. et al. Risk alleles for multiple sclerosis identified by a genomewide study. N. Engl. J. Med. 2007. 357: 851-862.
117. Lundmark, F., Duvefelt, K., Iacobaeus, E., Kockum, I., Wallstrom, E., Khademi, M., Oturai, A. et al., Variation in interleukin 7 receptor alpha chain (IL7R) influences risk of multiple sclerosis. Nat. Genet. 2007. 39: 1108-1113.
118. Teutsch, S. M., Booth, D. R., Bennetts, B. H., Heard, R. N. and Stewart, G. J., Identification of 11 novel and common single nucleotide polymorphisms in the interleukin-7 receptor-alpha gene and their associations with multiple sclerosis. Eur. J. Hum. Genet. 2003. 11: 509-515.